Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pohl, C.
Right arrow Articles by Harbrecht, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pohl, C.
Right arrow Articles by Harbrecht, U.
Related Collections
Right arrow All Medical/Systemic disease
Right arrow Hematologic
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2005;64:1285-1287
© 2005 American Academy of Neurology
Brief Communications

Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin

C. Pohl, MD, A. Kredteck, B. Bastians, MD, P. Hanfland, MD, T. Klockgether, MD and U. Harbrecht, MD

From the Department of Neurology (Drs. Pohl and Klockgether) and Institute of Experimental Haematology and Transfusion Medicine (Drs. Har-brecht, Kredteck, Bastians, and Hanfland), University Hospital Bonn, Germany.

Address correspondence and reprint requests to Dr. U. Harbrecht, Institute of Experimental Hematology and Transfusion Medicine, Sigmund-Freud-Straße, D-53105 Bonn, Germany; e-mail: ursula.harbrecht{at}ukb.uni-bonn.de

The authors prospectively studied the risk for immune-mediated heparin-induced thrombocytopenia (HIT) in neurologic patients during administration of low-molecular-weight heparin (LMWH) vs unfractionated heparin (UFH). None of 111 neurologic patients receiving LMWH developed HIT, whereas HIT occurred in 2.5% of 200 patients treated with UFH (p = 0.17). The rate of heparin-induced antibodies in patients treated with LMWH was lower than in patients treated with UFH (1.8 vs 20.5%; p < 0.001).

Dr. Pohl’s current address is Schering AG, Berlin, Germany.

Received September 22, 2004. Accepted in final form December 23, 2004.




This article has been cited by other articles:


Home page
 ChestHome page
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 340S - 380S.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood, November 1, 2006; 108(9): 2937 - 2941.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. M. Arepally and T. L. Ortel
Heparin-Induced Thrombocytopenia
N. Engl. J. Med., August 24, 2006; 355(8): 809 - 817.
[Full Text] [PDF]

Home page
 BloodHome page
T. E. Warkentin and A. Greinacher
Unfractionated LMWH and the risk of HIT: are medical patients different?
Blood, November 1, 2005; 106(9): 2931 - 2932.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.